from 01.01.2019 to 01.01.2023
Russian Federation
The aim of the study. To evaluate the e—ect of glucose-lowering therapy regimens on the parameters of systolic and diastolic function of the left ventricle in type 2 diabetes mellitus (DM 2). Material and methods. The study included 79 patients with DM 2 and chronic heart failure. Patients were randomized into 4 comparable groups. Cardiac parameters were assessed at baseline, after 3 and 12 months. Results. During 3 months of treatment, there were no changes in systolic parameters. After 12 months, in groups 1 and 2, an increase in the end-systolic size was noted, in group 3 its value did not change, and in group 4, a downward trend appeared. The end-systolic volume increased in groups 1, 2, and 3, while there were no changes in group 4. The ejection fraction and isovolumic relaxation time decreased in groups 1-3 and did not change in group 4. The left atrium increased in size after 12 months in groups 1, 2, and 3, while in group 4, on the contrary, it regressed from 4.6±0.04 to 4.3±0.01 cm. The end-diastolic size and end-diastolic volume increased in groups 1, 2, and 3, while they did not change in group 4. The E peak decreased in all groups, while in group 4 it increased from 75.2±2.2 to 79.3±1.5 cm/s. The A peak did not change in groups 1, 2, and 3, while in group 4 it decreased from 77.5±1.7 to 75.4±0.8 cm/s. The isovolumic relaxation time increased in group 1, while it decreased in groups 2, 3, and 4. The early diastolic †lling deceleration time increased in groups 1, 2, and 3, while it decreased in group 4. Conclusions. The combination of sodium glucose cotransporter 2 inhibitors with metformin has a bene†cial e—ect on ventricular systolic-diastolic parameters.
Diabetes Mellitus, Type 2; Heart Failure; Heart Ventricles; Metformin; Sodium Glucose Transporter 2 Inhibitors; Stroke Volume
1. Baldi J. C., Aoina J. L., Whalley G. A., et al. The effect of type 2 diabetes on diastolic function. Med. Sci. Sports Exerc. 2006;38(8):1384-1388. doi:https://doi.org/10.1249/01.mss.0000228954.90591.95.
2. Grazhdankina D. V., Demin A. A., Bondar I. A. Predictors of the initial stage of chronic heart failure in type 2 diabetes mellitus. Journal of Siberian Medical Sciences 2021;4:4-16. doihttps://doi.org/10.31549/25421174-2021-4-4-16. (In Russ.).
3. Pradeep S., Umarani R. Diastolic Dysfunction in Asymptomatic Type 2 Diabetes Mellitus with Normal Systolic Function. International Journal of Science and Research 2022;8:591-597. doihttps://doi.org/10.4103/0975-3583.89805.
4. Sun D., Zhu Z., Zhang Y., et al. Relation of genetic polymorphisms in microRNAs with diastolic and systolic function in type 2 diabetes mellitus. J. Nutr. Metab. Cardiovasc. Dis. 2022;32(12):28772882.
5. Lang R. M., Bierig M., Devereux R. B., et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification
6. Foudad H., Latreche S., Quessar A., et al. Relationship between left ventricular diastolic dysfunction and coronary disease in type 2 diabetes mellitus. Ann. Cardiol. Angeiol. 2021;70(2):81-85. doihttps://doi.org/10.1016/j.ancard.2020.11.008.
7. Leung M., Wong V. W., Hudson M., Leung D. Y. Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus. Circ. Cardiovasc. Imaging. 2016;9(3): e003643. doihttps://doi.org/10.1161/CIRCIMAGING.115.003643.
8. Tadic M., Suzic-Lazic J., Vukomanovic V. Functional capacity and left ventricular diastolic function in patients with type 2 diabetes. Acta Diabetol. 2021;58(1):107-113. doi:https://doi.org/10.1007/s00592020-01600-x.
9. Borisova E. V., Barsukov A. V., Glebova S. A., Airapetyan A. V. Effect of sodium-glucose cotransporter type 2 inhibitors on left ventricular diastolic function: current status and prospects. Cardiology. 2024;64(7):64-71. (In Russ.).
10. Kusunose K., Imai T., Tanaka A. et al. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes: A subanalysis of the PROTECT trial. PROTECT investigators. J. Cardiol. 2024;84(4):246-252.
11. Rybakova M. K., Mitkov V. V., Baldin D. G. Echocardiography from M.K. Rybakova. - M.: Publishing house Vidar M; 2018. (In Russ.).
12. Useinova R. Kh., Beloglazov V. A., Yatskov I. A., Repinskaya I. N. Profiles of changes in blood pressure and indicators of vascular wall rigidity in patients with type 1 diabetes mellitus in the Republic of Crimea. Tavricheskiy
13. Yokota S., Tanaka H., Mochizuki Y., et al. Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus. Cardiovasc. Diabetol. 2019;18(1):166. doihttps://doi.org/10.1186/s12933-019-0971-5.
14. Kamushadze G. K. Analysis of the efficacy and safety of modern antihypertensive drugs in the treatment of chronic heart failure. Cardiology 2024;4(39):33-38. (In Russ.). doihttps://doi.org/10.33029/23091908-2024-12-4-33-38.
15. Bogomolov A. N., Kozlov K. L., Kurochkina O. N. Epidemiology and modern strategies for the treatment of coronary heart disease in patients with type 2 diabetes mellitus. Cardiology 2024;4(39):5765. (In Russ.).
